BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Br J Cancer 2018;118:947-54. [PMID: 29515256 DOI: 10.1038/s41416-018-0004-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Verma H, Narendra G, Raju B, Singh PK, Silakari O. Dihydropyrimidine Dehydrogenase-Mediated Resistance to 5-Fluorouracil: Mechanistic Investigation and Solution. ACS Pharmacol Transl Sci . [DOI: 10.1021/acsptsci.2c00117] [Reference Citation Analysis]
2 Tsukahara S, Shiota M, Takamatsu D, Nagakawa S, Matsumoto T, Kiyokoba R, Yagi M, Setoyama D, Noda N, Matsumoto S, Hayashi T, Contreras-Sanz A, Black PC, Inokuchi J, Kohashi K, Oda Y, Uchiumi T, Eto M, Kang D. Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine. Sci Rep 2022;12:8535. [PMID: 35595780 DOI: 10.1038/s41598-022-12528-3] [Reference Citation Analysis]
3 Danesh Pouya F, Rasmi Y, Nemati M. Signaling Pathways Involved in 5-FU Drug Resistance in Cancer. Cancer Invest 2022;:1-28. [PMID: 35320055 DOI: 10.1080/07357907.2022.2055050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sturm N, Ettrich TJ, Perkhofer L. The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. Cancers (Basel) 2022;14:217. [PMID: 35008381 DOI: 10.3390/cancers14010217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Nguyen M, Segelov E, Goldstein D, Pavlakis N, Shapiro J, Price TJ, Nagrial A, Chantrill L, Leong T, Chen J, Burge M, Karapetis CS, Chau I, Lordick F, Renouf D, Tebbutt N, Roy AC. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther 2021;:1-13. [PMID: 34739362 DOI: 10.1080/14737140.2022.2002689] [Reference Citation Analysis]
6 Li J, Chen B, Xi WQ, Yang C, Zhang WX. Gene-Gene Interactions of Gemcitabine Metabolizing-Enzyme Genes hCNT3 and WEE1 for Preventing Severe Gemcitabine-Induced Hematological Toxicity. J Clin Pharmacol 2021;61:1376-85. [PMID: 33974709 DOI: 10.1002/jcph.1909] [Reference Citation Analysis]
7 Mauvais-Jarvis F, Berthold HK, Campesi I, Carrero JJ, Dakal S, Franconi F, Gouni-Berthold I, Heiman ML, Kautzky-Willer A, Klein SL, Murphy A, Regitz-Zagrosek V, Reue K, Rubin JB. Sex- and Gender-Based Pharmacological Response to Drugs. Pharmacol Rev 2021;73:730-62. [PMID: 33653873 DOI: 10.1124/pharmrev.120.000206] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 19.0] [Reference Citation Analysis]
8 Kato H, Naiki-Ito A, Suzuki S, Inaguma S, Komura M, Nakao K, Naiki T, Kachi K, Kato A, Matsuo Y, Takahashi S. DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer. Carcinogenesis 2021;42:940-50. [PMID: 33640964 DOI: 10.1093/carcin/bgab017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
9 Sethy C, Kundu CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed Pharmacother 2021;137:111285. [PMID: 33485118 DOI: 10.1016/j.biopha.2021.111285] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 29.5] [Reference Citation Analysis]
10 Mas L, Schwarz L, Bachet JB. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. Curr Opin Oncol 2020;32:356-63. [PMID: 32541325 DOI: 10.1097/CCO.0000000000000639] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
11 Gu ZT, Li ZZ, Wang CF. Research advances of intracellular mechanisms underlying gemcitabine resistance in pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2020; 28(22): 1150-1161 [DOI: 10.11569/wcjd.v28.i22.1150] [Reference Citation Analysis]
12 Real FX, Siveke JT. Pancreatic cancer transcriptomes: molecular stratification in the adjuvant setting. Ann Oncol 2021;32:133-5. [PMID: 33227409 DOI: 10.1016/j.annonc.2020.11.012] [Reference Citation Analysis]
13 Khomiak A, Brunner M, Kordes M, Lindblad S, Miksch RC, Öhlund D, Regel I. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Cancers (Basel) 2020;12:E3234. [PMID: 33147766 DOI: 10.3390/cancers12113234] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
14 Ke L, Yang DC, Wang Y, Ding Y, Gao G. AnnoLnc2: the one-stop portal to systematically annotate novel lncRNAs for human and mouse. Nucleic Acids Res 2020;48:W230-8. [PMID: 32406920 DOI: 10.1093/nar/gkaa368] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
15 Hwang DW, Shin E, Cho JY, Han HS, Yoon YS. Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer? Ann Hepatobiliary Pancreat Surg 2020;24:127-36. [PMID: 32457256 DOI: 10.14701/ahbps.2020.24.2.127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Chamorey E, Francois E, Etienne MC, Ferrero JM, Peyrade F, Barranger E, Bozec A, Largillier R, Cassuto O, Viotti J, Schiappa R, Milano G. DPD status and fluoropyrimidines-based treatment: high activity matters too. BMC Cancer 2020;20:436. [PMID: 32423482 DOI: 10.1186/s12885-020-06907-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Conroy T, Ducreux M. Adjuvant treatment of pancreatic cancer. Curr Opin Oncol 2019;31:346-53. [PMID: 30994497 DOI: 10.1097/CCO.0000000000000546] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
18 Siddiqui A, Ceppi P. A non-proliferative role of pyrimidine metabolism in cancer. Mol Metab 2020;35:100962. [PMID: 32244187 DOI: 10.1016/j.molmet.2020.02.005] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 16.0] [Reference Citation Analysis]
19 Okamura Y, Yasukawa S, Narimatsu H, Boku N, Fukutomi A, Konishi M, Morinaga S, Toyama H, Kaneoka Y, Shimizu Y, Nakamori S, Sata N, Yamakita K, Takahashi A, Kainuma O, Hishinuma S, Yamaguchi R, Nagino M, Hirano S, Yanagisawa A, Mori K, Uesaka K. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Cancer Sci 2020;111:548-60. [PMID: 31778273 DOI: 10.1111/cas.14258] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
20 Vos LJ, Yusuf D, Lui A, Abdelaziz Z, Ghosh S, Spratlin JL, Mackey JR. Predictive and Prognostic Properties of Human Equilibrative Nucleoside Transporter 1 Expression in Gemcitabine-Treated Pancreatobiliary Cancer: A Meta-Analysis. JCO Precision Oncology 2019. [DOI: 10.1200/po.18.00240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Merloni F, Ranallo N, Scortichini L, Giampieri R, Berardi R. Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase. Cancer Drug Resist 2019;2:787-802. [PMID: 35582578 DOI: 10.20517/cdr.2018.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
22 Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in Pancreatic Cancer. Int J Mol Sci 2019;20:E4504. [PMID: 31514451 DOI: 10.3390/ijms20184504] [Cited by in Crossref: 163] [Cited by in F6Publishing: 179] [Article Influence: 40.8] [Reference Citation Analysis]
23 Mahajan UM, Goni E, Langhoff E, Li Q, Costello E, Greenhalf W, Kruger S, Ormanns S, Halloran C, Ganeh P, Marron M, Lämmerhirt F, Zhao Y, Beyer G, Weiss FU, Sendler M, Bruns CJ, Kohlmann T, Kirchner T, Werner J, D'Haese JG, von Bergwelt-Baildon M, Heinemann V, Neoptolemos JP, Büchler MW, Belka C, Boeck S, Lerch MM, Mayerle J. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. JNCI Cancer Spectr 2020;4:pkz060. [PMID: 32296755 DOI: 10.1093/jncics/pkz060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 El Hassouni B, Li Petri G, Liu DSK, Cascioferro S, Parrino B, Hassan W, Diana P, Ali A, Frampton AE, Giovannetti E. Pharmacogenetics of treatments for pancreatic cancer. Expert Opin Drug Metab Toxicol 2019;15:437-47. [PMID: 31100206 DOI: 10.1080/17425255.2019.1620731] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
25 Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Chemotherapy for pancreatic cancer. Presse Med 2019;48:e159-74. [PMID: 30879894 DOI: 10.1016/j.lpm.2019.02.025] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 18.8] [Reference Citation Analysis]
26 Zemanek T, Melichar B, Lovecek M, Soucek P, Mohelnikova-Duchonova B. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. Pharmacogenomics 2019;20:113-27. [PMID: 30539680 DOI: 10.2217/pgs-2018-0073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]